Core Viewpoint - The company's 1H25 performance aligns with expectations, showing revenue growth but a decline in net profit, indicating a mixed financial outlook amid evolving market conditions [1][2]. Financial Performance - Revenue for 1H25 reached 6.01 billion, an 18.3% year-on-year increase, while net profit attributable to shareholders was 500 million, a 30.8% decline. Adjusted net profit after stock incentive expenses was 740 million, down 2.1% [1]. - The company declared an interim dividend of 0.2 HKD per share, with a payout ratio of 225.1%, significantly higher than the 38.7% in 1H24, indicating increased shareholder returns [1]. Market Trends - The ToB revenue grew by 19.5% to 4.739 billion, driven by strong performance in Europe and potential improvements in the U.S. market due to stricter regulations [1]. - In Europe, revenue surged by 38% to 2.73 billion, benefiting from regulatory changes that favored compliant companies [1]. - U.S. revenue increased by 1.5% to 1.89 billion, with expectations of continued improvement as enforcement tightens [1]. - Domestic revenue, however, saw a decline of 6.1% to 120 million [1]. Product Development - The ToC revenue rose by 14.1% to 1.274 billion, with significant growth in the APV segment, particularly in Europe, where new product launches are driving user conversion [2]. - The APV revenue in Europe and the U.S. was 1.07 billion and 170 million, respectively, with declines of 15.1% and 6.7% [2]. - The nebulization beauty segment experienced a remarkable growth of 2595% to 30.618 million, with over 10,000 C-end users and more than 100 B-end partnerships established [2]. Profitability and Costs - The overall gross margin remained stable, decreasing slightly by 0.5 percentage points to 37.3%. However, the net profit margin fell by 5.9 percentage points to 8.3%, and adjusted for stock incentive expenses, it decreased by 1.2 percentage points to 12.3% [2]. - Sales expense ratio increased by 0.8 percentage points to 8.2% due to heightened investment in self-owned brands, while R&D expense ratio decreased by 2.9 percentage points to 12% [2]. - Management expenses rose significantly by 15.5 percentage points to 22.2%, primarily due to increased stock incentive costs [2]. Growth Outlook - The HNB segment is expected to accelerate globally, with Glo Hilo's market share in Japan increasing by 1.5% during its sales period, indicating strong growth potential [3]. - The regulatory environment for vaping products in Europe and the U.S. is expected to lead to a more standardized industry, allowing the company to recover market share and continue growing [3]. - The company is also focusing on developing nebulization medical products and expanding its nebulization beauty segment domestically, which opens up additional growth opportunities [3]. Profit Forecast and Valuation - The company maintains its profit forecast and industry outperform rating, with a target price reflecting a 4% upside from the current stock price [3].

Core Viewpoint - UBS has downgraded the target price for Smoore International (06969) to HKD 13.11 and maintained a "Sell" rating due to a decline in mid-term net profit primarily driven by increased equity compensation, rising sales and development expenses, and a higher tax rate [1] Financial Performance - Smoore International's mid-term net profit has decreased, largely attributed to increased equity compensation and higher sales and development expenditures [1] - The company's management remains optimistic about revenue growth in the second half of the year, citing favorable policies for e-cigarettes in the US and Europe [1] Future Outlook - Short-term profitability is expected to be impacted by increased R&D spending as the company prepares to launch its own products in the US [1] - More specific financial results from new business segments such as heated tobacco, inhalation therapy, and beauty aerosol products are anticipated to be reflected by 2027 [1] Earnings Forecast - UBS has revised its earnings forecast for Smoore International for the years 2023 to 2027 down by 10% to 33%, reflecting higher sales, marketing, and R&D expenses [1]

Core Viewpoint - UBS report indicates that Smoore International's mid-term net profit has declined primarily due to increased equity compensation, rising sales and development expenses, and higher tax rates [1] Financial Performance - The management is optimistic about continued revenue growth in the second half of the year, supported by favorable e-cigarette policies in the US and Europe [1] - The company’s short-term profitability is still impacted by increased R&D expenses as it prepares to launch its own products in the US [1] Future Outlook - Management expects more specific financial results from new business segments such as heated tobacco, inhalation therapy, and beauty aerosol products to be reflected by 2027 [1] - UBS has lowered its earnings forecast for the company from this year to 2027 by 10% to 33%, reflecting higher sales, marketing, and R&D expenses [1] Target Price and Rating - The target price has been reduced from HKD 14 to HKD 13.11, while maintaining a "Sell" rating [1]

Core Viewpoint - UBS report indicates that Smoore International (06969) experienced a decline in mid-term net profit primarily due to increased equity compensation, rising sales and development expenses, and higher tax rates [1] Financial Performance - The management remains optimistic about revenue growth in the second half of the year, supported by favorable e-cigarette policies in the US and Europe [1] - The company’s short-term profitability is still impacted by higher R&D expenditures as it prepares to launch its own products in the US [1] Future Outlook - More specific financial results from new business segments such as heated tobacco, inhalation therapies, and beauty aerosol products are expected to be reflected by 2027 [1] - UBS has revised its earnings forecast for the company downwards by 10% to 33% for the years 2023 to 2027, reflecting increased sales, marketing, and R&D expenses [1] Target Price Adjustment - The target price for Smoore International has been reduced from HKD 14 to HKD 13.11, while maintaining a "Sell" rating [1]

Investment Rating - The investment rating for the company is "Buy" and is maintained [9] Core Views - The company achieved a revenue of 6.013 billion HKD in H1 2025, representing an 18% year-on-year increase. However, net profit was 492 million HKD, down 28% year-on-year, while adjusted net profit was 737 million HKD, a decrease of 2% year-on-year. The company also reported a share-based payment expense of 245 million HKD for H1 2025 and declared an interim dividend of 0.2 HKD per share, totaling approximately 1.24 billion HKD in dividends to shareholders [2][6] Revenue Analysis - The revenue growth in H1 2025 was primarily driven by the recovery of the vaping business. Specifically, the TOB (business-to-business) segment saw a 19% year-on-year increase, accounting for 79% of total revenue. Revenue from the TOB segment in the US, mainland China, Europe, and other regions showed varied performance, with increases of 1%, decreases of 6%, and increases of 38% respectively. The TOC (business-to-consumer) segment also grew by 14%, making up 21% of total revenue, with significant growth in mainland China at 2595% year-on-year [10] Profitability Analysis - The overall performance met the central expectations of the earnings forecast, with adjusted profits down 2% year-on-year. The decline in net profit was attributed to insufficient revenue and gross profit growth to offset rising expenses, including a significant increase in share-based payment expenses due to a stock incentive plan launched in late 2024. Additionally, distribution and sales expenses rose by 31% to 491 million HKD, and professional fees related to legal and compliance services surged by 820% to 140 million HKD [10] HNB Business Development - A significant milestone for the company in H1 2025 was the launch of Glo Hilo in collaboration with British American Tobacco. The product received positive consumer feedback during trials in Serbia and Sendai, Japan, with highlights including a close-to-tobacco flavor and reduced preheating time. The company plans to expand Glo Hilo across Japan in September 2025 and into more key markets later in the year. The company aims to continue investing in R&D for HNB products to maintain technological leadership and enhance customer adoption rates [10] Growth Potential - The company is optimistic about its growth potential in the global new tobacco trend. The vaping segment is showing signs of recovery, benefiting from regulatory shifts and increased market share among major clients. The HNB business has significant growth potential, especially considering the current market share of IQOS at over 70%. The industry is expected to continue growing at a double-digit annual rate, with ample room for penetration as the current global penetration rate is only about 6%. Long-term growth trends are also positive for medical vaping and special-purpose vaping [10]

思摩尔国际 20250825 思摩尔国际 ODM 业务表现良好，尤其是在欧洲禁售一次性电子烟政策 下，代工业务率先修复。HNB 产品在日本试销获得积极反馈，并计划在 欧洲等市场陆续上市，预计将实现放量增长。 思摩尔国际对应 2025-2027 年的预测 PE 分别为 95 倍、60 倍和 42 倍， 估值较高，但基于行业前景和公司研发实力，市值解锁目标 3,000 亿可 期。 新型烟草三种形态（电子雾化、HNB、口含烟）目前渗透率均较低，不 存在直接竞争，各自满足不同减害需求，将在长期内共存并共同推动市 场发展。 新型烟草有哪些主要类型？它们各自的发展情况如何？ 目前，新型烟草主要有三种类型：电子雾化烟、加热不燃烧（HNB）和口含烟 或尼古丁袋。电子雾化烟大约在 2000 年左右在中国诞生，经历了快速发展后， 由于全球政策监管收紧，自 2021 年起略有下行。加热不燃烧产品由菲莫国际 于 2014 年开创，通过降低温度减少有害物质释放，同时保留尼古丁摄取，自 发布以来经历了近十年的快速增长，但由于欧洲等国家对调味加热不燃烧产品 的监管，其增速近两年下滑至中低双位数水平。口含烟或尼古丁袋则通过口腔 黏膜吸收尼古 ...

Summary of Conference Call Notes Industry Overview - The Japanese HNB (Heated Not Burned) market has a global penetration rate of 43% in 2024, significantly higher than other countries, indicating substantial growth potential in the new tobacco market [1][3] - The global traditional cigarette market has an HNB penetration rate of less than 6%, highlighting the early development stage of this category [1][8] Market Dynamics - The Japanese new tobacco market is characterized by a "one leader, two strong" structure, with Philip Morris International (PMI) holding a 70% market share, followed by British American Tobacco (BAT) and Japan Tobacco with 15-16% and 14% respectively [1][4] - BAT has shifted some resources from its Hyper product line to Hilo, which is positioned in the high-end market, competing directly with PMI's IQOS [1][10] Product Launch and Promotion - Smoore International launched its new product in Miyagi Prefecture, a region with a high HNB penetration rate of 56%, facilitating product education and promotion [1][5] - The new products are prominently displayed in major convenience stores in Sendai, indicating successful initial promotion [1][5] Product Differentiation - Major brands in Japan have distinct product design philosophies: Japan Tobacco's Pro series uses low-temperature heating, PMI's IQOS is mid-range, and BAT's GLO Helo series targets high-temperature, high-volume consumers [1][6] Global Market Comparison - Other countries lag in HNB development, with penetration rates of 20% in Italy, 18% in South Korea, 16% in Ukraine, and 14% in Poland [1][7] Sales and Distribution - Convenience stores like Seven Eleven have effectively distributed tobacco products, with BAT's PROOM series occupying prime shelf space [1][9] Future Plans and Market Strategy - Smoore plans to fully launch its new products in Japan on September 1 and enter the European market by the end of the year, aiming to validate repurchase rates and consumer acceptance [1][14] - BAT aims to increase its new tobacco revenue share to over 50% within the next decade, reflecting a positive market outlook [1][18] Regulatory and Competitive Challenges - The high entry barriers in the new tobacco industry, coupled with recent regulatory changes in China prohibiting HNB production, pose significant challenges for new entrants [1][17] - Investors should monitor product sales feedback and industry dynamics, as Smoore's competitive advantage is supported by high industry barriers and BAT's brand channel support [1][2][15] Investment Outlook - Investors are encouraged to evaluate the new tobacco industry trends and competitive landscape, as there are positive signs in the Japanese market within a short promotional period [1][20]

Core Viewpoint - The company reported a revenue of 6.013 billion yuan for the first half of 2025, marking an 18.3% year-on-year increase, while net profit decreased by 28.0% to 492 million yuan [1] Financial Performance - Revenue for H1 2025 reached 6.013 billion yuan, up 18.3% year-on-year [1] - Gross profit was 2.244 billion yuan, a 16.6% increase, with a gross margin of 37.3%, down 0.5 percentage points [1] - Net profit fell to 492 million yuan, a decrease of 28.0%, while adjusted net profit was 737 million yuan, down 2.1% [1] - Adjusted net profit margin stood at 12.3%, down 2.5 percentage points year-on-year [1] Segment Performance - Self-owned brand revenue from electronic vapor products and vapor beauty products was 1.274 billion yuan, up 14.1%, accounting for 21.2% of total revenue [1] - Revenue from the European and other regions was 1.069 billion yuan, a 15.1% increase, driven by the strong performance of the VAPORESSO brand [2] - The U.S. market revenue was 174 million yuan, down 6.7%, while the Chinese market saw a significant increase of 2595.2% to 30.618 million yuan, mainly from the "岚至" brand [2] - Revenue from enterprise clients was 4.739 billion yuan, up 19.5%, making up 78.8% of total revenue [2] Regulatory Environment - Increased enforcement against non-compliant products in the U.S. has been noted, with the FDA and CBP seizing over 135 million USD worth of illegal e-cigarettes [2] - In Europe, several countries have imposed restrictions or bans on disposable e-cigarettes, with the UK implementing a sales ban on June 1, 2025 [2] R&D and Future Growth - The company successfully supported the launch of the high-end HNB product Hilo series, set to be released in Japan in September 2025 [3] - The vapor medical subsidiary is developing leading asthma and COPD products for the U.S. and European markets, aiming for greater revenue contributions [3] - The "岚至" home beauty device has surpassed 10,000 users, and the professional equipment has received Class II medical device certification [3] - R&D expenditure for H1 2025 was 723 million yuan, down approximately 4.9%, representing about 12.0% of revenue [3] Profit Forecast and Investment Outlook - The company is expected to benefit from increased market concentration due to stricter regulations, with significant contributions from HNB business anticipated from 2026 [3] - Adjusted net profit forecasts for 2025-2027 are 1.472 billion, 1.979 billion, and 2.663 billion yuan, respectively, with year-on-year growth of 34.40% and 34.60% in 2026 and 2027 [3]

Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 6.013 billion yuan, a year-on-year increase of 18.3%, aligning with forecast values and exceeding early-year high single-digit expectations [1] - The net profit was 492 million yuan, a year-on-year decrease of 28.0%, which is the midpoint of the forecast range, attributed to increased management expenses and legal compliance costs [1] - Adjusted net profit was 737 million yuan, a year-on-year decline of 2.1%, also within the forecast range [1] - The company's gross margin for H1 was 37.3%, a decrease of 0.5 percentage points year-on-year, while the adjusted net profit margin was 12.3%, an increase of 2.5 percentage points year-on-year [1] Group 2: Business Segments - The self-owned brand business generated revenue of 1.274 billion yuan in H1, a year-on-year increase of 14.1%, with European revenue growing by 15.1% [1] - The To B business revenue was 4.739 billion yuan, a year-on-year increase of 19.5%, with European revenue rising by 38.0% [2] - The HNB market is experiencing rapid growth, with the company collaborating with British American Tobacco on the HNB product gloHilo, which received positive feedback during trials in Japan [2] Group 3: Market Outlook and Projections - The company is adjusting its profit forecasts due to the impact of incentive amortization and other expenses, projecting net profits of 1.33 billion, 2.22 billion, and 2.89 billion yuan for 2025-2027 [3] - The company maintains a "buy" rating, with projected P/E ratios of 100, 60, and 46 for the respective years [3]

Core Viewpoint - Smoore International, the world's largest electronic vapor product manufacturer, reported a revenue of 6.013 billion RMB for the first half of 2025, an increase of 18.3% year-on-year, while adjusted net profit decreased by 2.1% to 737 million RMB [1] Group 1: Financial Performance - The company proposed an interim dividend of 0.20 HKD per share, with a payout ratio increasing to 225.1%, compared to approximately 38.7% in the same period of 2024 [1] - The self-owned brand business generated approximately 1.274 billion RMB in revenue, a year-on-year increase of about 14.1%, accounting for approximately 21.2% of total revenue [1] Group 2: Brand and Market Performance - The self-owned brand "Lanzhi" in mainland China generated approximately 31 million RMB in revenue, showing a significant year-on-year growth of about 2595.2% [2] - The "Lanzhi" home beauty device has surpassed 10,000 users, and the professional equipment has received Class II medical device certification, being adopted by over 100 private institutions [2] Group 3: Business Segments - The To B (business-to-business) segment recorded revenue of approximately 4.739 billion RMB, a year-on-year increase of about 19.5%, driven mainly by the recovery of the electronic vapor business [2] - The company successfully supported key clients in launching a series of innovative compliant products in response to regulatory changes in the European market, leading to strong order growth [2] Group 4: Research and Development - The company focused on enhancing R&D efficiency, prioritizing investments in heated non-combustible (HNB) products and vapor medical applications, achieving several breakthroughs in R&D [3] - A significant milestone was the successful support of a strategic client in launching a high-end HNB product series in key markets, with plans for a nationwide launch in Japan by September 2025 [3] Group 5: Future Outlook - The company aims to continue leveraging technological innovation as a foundation, focusing on electronic vapor, heated non-combustible, special-purpose vapor products, vapor medical, and vapor beauty sectors to provide comprehensive vapor technology solutions [3]